Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-09-27

Clinical Trial Update: Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update assessing the effect of tiotropium + olodaterol on breathlessness in COPD patients; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tiotropium + Olodaterol (tiotropium/olodaterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2019-09-27